Logo

Gilead's Vemlidy (Tenofovir Alafenamide) Receives NMPA (CFDA) Approval for Chronic Hepatitis B Virus (HBV) Infection"

Share this

Gilead's Vemlidy (Tenofovir Alafenamide) Receives NMPA (CFDA) Approval for Chronic Hepatitis B Virus (HBV) Infection"

 Shots:

  • The approval is based on the results of two international P-III 108 and 110 study assessing Vemlidy vs Viread in 1-632 patients with HBeAg-negative and HBeAg-positive HBV disease for duration of 96 wks.
  • The study demonstrated improved renal and bone safety symbols when compared to Viread. The US Prescribing Information involves a box warning for Vemlidy with its discontinuation can cause risk of post-treatment severe acute exacerbation of hepatitis B
  • Vemlidy 25mg is a qd remedy indicated for chronic hepatitis B in adults and adolescents (aged ≥12 yrs with body weight ≥35 kg) and is approved by FDA for compensated liver disease in adults

Ref: Gilead | Image: Gilead


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions